Literature DB >> 26799749

New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs.

Lucie Pouché1,2, Jana Stojanova3, Pierre Marquet1,2,4,5, Nicolas Picard1,2,4,5.   

Abstract

Interindividual variability in immunosuppressive drug responses might be partly explained by genetic variants in proteins involved in the immune response or associated with IS pharmacodynamics. On a general basis, the pharmacogenetics of drug target proteins is less known and understood than that of proteins involved in drug disposition pathways. The aim of this review is to facilitate research related to the pharmacodynamics of the main immunosuppressive drugs used in solid organ transplantation. We elaborated a quality of evidence grading system based on a literature review and identified 'highly recommended', 'recommended' or 'potential' candidates for further research. It is likely that a number of additional rare variants might further explain drug response phenotypes in transplantation, and particularly the most severe ones. The advent of next-generation sequencing will help to identify those variants.

Keywords:  calcineurin; gene polymorphism; inosine monophosphate dehydrogenase; mammalian target of Rapamycin; personalized medicine; pharmacology

Mesh:

Substances:

Year:  2016        PMID: 26799749     DOI: 10.2217/pgs.15.169

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  7 in total

Review 1.  Applying genomics in heart transplantation.

Authors:  Brendan J Keating; Alexandre C Pereira; Michael Snyder; Brian D Piening
Journal:  Transpl Int       Date:  2018-02-12       Impact factor: 3.782

2.  Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid.

Authors:  Lin Cheng; Pu Yao; Bangbi Weng; Ming Yang; Qian Wang
Journal:  Eur J Clin Pharmacol       Date:  2022-05-07       Impact factor: 3.064

3.  Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients.

Authors:  Rui Dai; Jingjie Li; Jingjing Wu; Qian Fu; Jiajia Yan; Guoping Zhong; Changxi Wang; Xiao Chen; Pan Chen
Journal:  Eur J Clin Pharmacol       Date:  2020-08-15       Impact factor: 2.953

4.  Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.

Authors:  Sabrina Falkowski; Jean-Baptiste Woillard; Deborah Postil; Nicole Tubiana-Mathieu; Eric Terrebonne; Antoine Pariente; Denis Smith; Rosine Guimbaud; Claire Thalamas; Koukeb Rouguieg-Malki; Pierre Marquet; Nicolas Picard
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

5.  Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients.

Authors:  Patricia C Salgado; Fabiana Dv Genvigir; Claudia R Felipe; Helio Tedesco-Silva; Jose O Medina-Pestana; Sonia Q Doi; Mario H Hirata; Rosario Dc Hirata
Journal:  Pharmgenomics Pers Med       Date:  2017-03-31

6.  Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients.

Authors:  Antony Brayan Campos-Salazar; Fabiana Dalla Vecchia Genvigir; Claudia Rosso Felipe; Helio Tedesco-Silva; José Medina-Pestana; Gabriela Vieira Monteiro; Rodrigo de Gouveia Basso; Alvaro Cerda; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Front Pharmacol       Date:  2018-11-14       Impact factor: 5.810

7.  Impact of mTOR gene polymorphisms and gene-tea interaction on susceptibility to tuberculosis.

Authors:  Mian Wang; Shu-Juan Ma; Xin-Yin Wu; Xian Zhang; Julius Abesig; Zheng-Hui Xiao; Xin Huang; Hai-Peng Yan; Jing Wang; Meng-Shi Chen; Hong-Zhuan Tan
Journal:  World J Clin Cases       Date:  2020-10-06       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.